Sucampo Pharma. Inc (SCMP) 11.89 $SCMP
Paul Edick Joins Sucampo's Board of Directors
GlobeNewswire - Fri Jul 29, 5:30AM CDT
Sucampo Pharmaceuticals, Inc. (Sucampo) (NASDAQ:SCMP), a global biopharmaceutical company, today announced that Paul Edick will join Sucampo's Board of Directors on August 1. Mr. Edick is the former CEO of Durata Therapeutics and currently the founding partner of 3G Advisors.
SCMP: 11.89 (+0.14)
Sucampo to Stop Developing Cobiprostone for Oral Mucositis
Zacks Equity Research - Zacks Investment Research - Tue Jul 12, 7:28PM CDT
Sucampo Pharmaceuticals, Inc. (SCMP) announced that it will discontinue the development of its pipeline candidate, cobiprostone.
JNJ: 125.40 (+0.17), PFE: 37.31 (+0.42), SCMP: 11.89 (+0.14)
Sucampo Provides Update on Cobiprostone Development Program
GlobeNewswire - Mon Jul 11, 6:30AM CDT
Sucampo Pharmaceuticals, Inc. (Sucampo) (NASDAQ:SCMP), a global biopharmaceutical company, today announced the decision to discontinue the development of cobiprostone based on the results of a prespecified futility analysis of the Phase 2a study of an oral spray formulation of cobiprostone for the prevention of oral mucositis in patients that are undergoing radio chemotherapy for head and neck cancer. The futility analysis indicated that the clinical benefit of cobiprostone was insufficient to support continuation of the study. There were no safety concerns identified and cobiprostone demonstrated a well-tolerated safety profile consistent with earlier Phase 1 studies.
SCMP: 11.89 (+0.14)
Sucampo Pharmaceuticals Announces Webcast of Its Presentation at the Jefferies 2016 Healthcare Conference
GlobeNewswire - Tue May 31, 5:45AM CDT
Sucampo Pharmaceuticals, Inc. (Sucampo) (Nasdaq:SCMP), a global biopharmaceutical company, today announced that it will webcast its corporate presentation at the Jefferies 2016 Healthcare Conference on Tuesday, June 7th at 2:30 PM ET.
SCMP: 11.89 (+0.14)
AWS Morning Technical Breakdown Highlights: Novo Nordisk, Biodel, Sucampo Pharma, and SciClone Pharma
ACCESSWIRE - Mon May 23, 8:16AM CDT
LONDON, UK / ACCESSWIRE / May 23, 2016 / ActiveWallSt.com announces the list of stocks featured in the Technical Morning Blog. Every morning the Active Wall St. team discusses the latest news and technical events impacting stocks and the financial markets. Companies recently featured in the blog include Novo Nordisk, Biodel, Sucampo Pharma, and SciClone Pharma.
NVO: 57.05 (+0.08), SCMP: 11.89 (+0.14), SCLN: 10.88 (+0.32), BIOD: 0.41 (-0.03)
Sucampo Pharmaceuticals Announces Webcast of Its Presentation at the 2016 UBS Global Healthcare Conference
GlobeNewswire - Tue May 17, 5:45AM CDT
Sucampo Pharmaceuticals, Inc. (Sucampo) (Nasdaq:SCMP), a global biopharmaceutical company, today announced that it will webcast its corporate presentation at the 2016 UBS Global Healthcare Conference on Tuesday, May 24 at 3:30 PM ET.
SCMP: 11.89 (+0.14)
Upgrade Alert for Sucampo Pharmaceuticals (SCMP)
Comtex SmarTrend(R) - Fri May 06, 3:48AM CDT
Sucampo Pharmaceuticals (NASDAQ:SCMP) was upgraded from Hold to Buy at WallachBeth today. The stock closed yesterday at $10.22 on volume of 1.1 million shares, above average daily volume of 544,000. Sucampo Pharmaceuticals, Inc. researches and develops drugs based on protones, which are derived from functional fatty acids. The Company produces a prescription drug for the treatment of chronic idiopathic constipation.
SCMP: 11.89 (+0.14)
3 Cheap Growth Stocks You Can Buy Right Now
Sean Williams, The Motley Fool - Motley Fool - Thu May 05, 8:33AM CDT
While the market was in nearly nonstop rally mode for most of the past six years, investors didn't need to look far to uncover an abundance of growth stocks. But not all growth stocks are created equal. While some look poised to deliver extraordinary...
WYN: 69.69 (-1.33), SCMP: 11.89 (+0.14), NVR: 1,698.00 (-7.00)
Sucampo reports 1Q loss
Automated Insights - Wed May 04, 5:38AM CDT
ROCKVILLE, Md. (AP) _ Sucampo Pharmaceuticals Inc. (SCMP) on Wednesday reported a first-quarter loss of $4.1 million, after reporting a profit in the same period a year earlier.
SCMP: 11.89 (+0.14)
Sucampo Reports Strong Results for First Quarter of 2016
GlobeNewswire - Wed May 04, 5:30AM CDT
Results Driven by 60% Growth in Revenue
SCMP: 11.89 (+0.14)
Sucampo Pharmaceuticals Announces Webcast of Its Presentation at the Bank of America Merrill Lynch 2016 Healthcare Conference
GlobeNewswire - Tue May 03, 5:45AM CDT
Sucampo Pharmaceuticals, Inc. (Sucampo) (Nasdaq:SCMP), a global biopharmaceutical company, today announced that it will webcast its corporate presentation at the Bank of America Merrill Lynch 2016 Healthcare Conference on Tuesday, May 10 at 11:20 AM PT or 2:20 PM ET.
SCMP: 11.89 (+0.14)
CORRECTING and REPLACING Sucampo Standardizes on Veeva Vault for a Single Source of Truth and Enterprise-wide Capability
BusinessWire - Thu Apr 28, 9:44AM CDT
Headline of release should read: Sucampo Standardizes on Veeva Vault for a Single Source of Truth and Enterprise-wide Capability (instead of Sucampo Standardizes on Veeva Vault for a Single Source of Truth Enterprise-wide)
VEEV: 38.27 (+0.28), SCMP: 11.89 (+0.14)
Newest Release of Veeva Vault Streamlines Global Business Processes to Get Products to Market Faster and More Efficiently
BusinessWire - Thu Apr 28, 6:03AM CDT
Veeva Systems (NYSE: VEEV) introduced innovative features in its newest release of Veeva Vault, version 14. The Veeva Vault platform and suite of enterprise applications empower life sciences companies to streamline their business processes across an increasingly broad ecosystem of internal and external stakeholders.
VEEV: 38.27 (+0.28), SCMP: 11.89 (+0.14)
Sucampo Standardizes on Veeva Vault for a Single Source of Truth Enterprise-wide
BusinessWire - Thu Apr 28, 6:03AM CDT
Veeva Systems (NYSE:VEEV) announced today that Sucampo Pharmaceuticals (NASDAQ:SCMP), a fast-growing global biopharmaceutical company, has standardized on the Veeva Vault platform and suite of applications to provide a unified foundation for content and information management. Veeva's solution will help Sucampo eliminate information and process siloes across functional teams, regions, and partners, enabling Sucampo to make information fully accessible and actionable. Veeva Vault allows Sucampo to increase efficiency and strengthen compliance with a single source of truth for content plus life sciences-specific solutions that streamline key processes throughout the product lifecycle.
VEEV: 38.27 (+0.28), SCMP: 11.89 (+0.14)
Sucampo Announces First Quarter 2016 Earnings Call
GlobeNewswire - Wed Apr 20, 5:45AM CDT
Sucampo Pharmaceuticals, Inc. (Sucampo) (NASDAQ:SCMP), a global biopharmaceutical company, today announced that it will host its first quarter 2016 financial results teleconference and webcast at 8:30 a.m. Eastern on Wednesday, May 4th. The press release announcing the financial results and operating highlights is expected to be released before the opening of capital markets that day.
SCMP: 11.89 (+0.14)
Sucampo Reports Top-Line Data from Phase 2a Study of Cobiprostone in Patients with PPI-Refractory Non-Erosive Reflux Disease (NERD) and Symptomatic Gastroesophageal Reflux Disease (sGERD)
GlobeNewswire - Tue Apr 19, 6:00AM CDT
Sucampo Pharmaceuticals, Inc. (Sucampo) (NASDAQ:SCMP), a global biopharmaceutical company, today announced top-line data from a Phase 2a study of cobiprostone in patients with proton pump inhibitor (PPI)-refractory non-erosive reflux disease (NERD) or symptomatic gastroesophageal reflux disease (sGERD). While cobiprostone demonstrated significant benefit in some of the secondary measures of this exploratory study, the trial did not meet its primary endpoints and, based on these data, Sucampo intends to discontinue development of cobiprostone for PPI-refractory NERD/sGERD.
SCMP: 11.89 (+0.14)
Valeant (VRX) Receives Notice of Default: Stock in Trouble?
Zacks Equity Research - Zacks Investment Research - Wed Apr 13, 10:50AM CDT
Valeant Pharmaceuticals International, Inc. (VRX) announced that it has received a notice of default from its debtors.
VRX: 20.89 (-1.41), ARQL: 1.68 (+0.02), SCMP: 11.89 (+0.14), AMAG: 27.02 (+0.49)
Intercept's (ICPT) Ocaliva Gets Favorable FDA Panel Vote
Zacks Equity Research - Zacks Investment Research - Fri Apr 08, 2:35PM CDT
Intercept Pharmaceuticals, Inc. (ICPT) announced that the FDA's Gastrointestinal Drugs Advisory Committee has voted unanimously in favor of the company's lead pipeline candidate, Ocaliva.
ARQL: 1.68 (+0.02), SCMP: 11.89 (+0.14), ICPT: 169.72 (-3.31)
Intercept (ICPT) Up Ahead of Advisory Committee Meeting
Zacks Equity Research - Zacks Investment Research - Wed Apr 06, 10:10AM CDT
Shares of Intercept Pharmaceuticals, Inc. (ICPT) surged 13.3% just before the FDA Gastrointestinal Drug Advisory Committee's (GIDAC) meeting scheduled for Apr 7, 2016.
ECYT: 3.18 (unch), ARQL: 1.68 (+0.02), SCMP: 11.89 (+0.14), ICPT: 169.72 (-3.31)
Paul Edick Joins Sucampo's Board of Directors
GlobeNewswire - Fri Jul 29, 5:30AM CDT
Sucampo Pharmaceuticals, Inc. (Sucampo) (NASDAQ:SCMP), a global biopharmaceutical company, today announced that Paul Edick will join Sucampo's Board of Directors on August 1. Mr. Edick is the former CEO of Durata Therapeutics and currently the founding partner of 3G Advisors.
SCMP: 11.89 (+0.14)
Sucampo to Stop Developing Cobiprostone for Oral Mucositis
Zacks Equity Research - Zacks Investment Research - Tue Jul 12, 7:28PM CDT
Sucampo Pharmaceuticals, Inc. (SCMP) announced that it will discontinue the development of its pipeline candidate, cobiprostone.
JNJ: 125.40 (+0.17), PFE: 37.31 (+0.42), SCMP: 11.89 (+0.14)
Sucampo Provides Update on Cobiprostone Development Program
GlobeNewswire - Mon Jul 11, 6:30AM CDT
Sucampo Pharmaceuticals, Inc. (Sucampo) (NASDAQ:SCMP), a global biopharmaceutical company, today announced the decision to discontinue the development of cobiprostone based on the results of a prespecified futility analysis of the Phase 2a study of an oral spray formulation of cobiprostone for the prevention of oral mucositis in patients that are undergoing radio chemotherapy for head and neck cancer. The futility analysis indicated that the clinical benefit of cobiprostone was insufficient to support continuation of the study. There were no safety concerns identified and cobiprostone demonstrated a well-tolerated safety profile consistent with earlier Phase 1 studies.
SCMP: 11.89 (+0.14)
Sucampo Pharmaceuticals Announces Webcast of Its Presentation at the Jefferies 2016 Healthcare Conference
GlobeNewswire - Tue May 31, 5:45AM CDT
Sucampo Pharmaceuticals, Inc. (Sucampo) (Nasdaq:SCMP), a global biopharmaceutical company, today announced that it will webcast its corporate presentation at the Jefferies 2016 Healthcare Conference on Tuesday, June 7th at 2:30 PM ET.
SCMP: 11.89 (+0.14)
AWS Morning Technical Breakdown Highlights: Novo Nordisk, Biodel, Sucampo Pharma, and SciClone Pharma
ACCESSWIRE - Mon May 23, 8:16AM CDT
LONDON, UK / ACCESSWIRE / May 23, 2016 / ActiveWallSt.com announces the list of stocks featured in the Technical Morning Blog. Every morning the Active Wall St. team discusses the latest news and technical events impacting stocks and the financial markets. Companies recently featured in the blog include Novo Nordisk, Biodel, Sucampo Pharma, and SciClone Pharma.
NVO: 57.05 (+0.08), SCMP: 11.89 (+0.14), SCLN: 10.88 (+0.32), BIOD: 0.41 (-0.03)
Sucampo Pharmaceuticals Announces Webcast of Its Presentation at the 2016 UBS Global Healthcare Conference
GlobeNewswire - Tue May 17, 5:45AM CDT
Sucampo Pharmaceuticals, Inc. (Sucampo) (Nasdaq:SCMP), a global biopharmaceutical company, today announced that it will webcast its corporate presentation at the 2016 UBS Global Healthcare Conference on Tuesday, May 24 at 3:30 PM ET.
SCMP: 11.89 (+0.14)
Upgrade Alert for Sucampo Pharmaceuticals (SCMP)
Comtex SmarTrend(R) - Fri May 06, 3:48AM CDT
Sucampo Pharmaceuticals (NASDAQ:SCMP) was upgraded from Hold to Buy at WallachBeth today. The stock closed yesterday at $10.22 on volume of 1.1 million shares, above average daily volume of 544,000. Sucampo Pharmaceuticals, Inc. researches and develops drugs based on protones, which are derived from functional fatty acids. The Company produces a prescription drug for the treatment of chronic idiopathic constipation.
SCMP: 11.89 (+0.14)
3 Cheap Growth Stocks You Can Buy Right Now
Sean Williams, The Motley Fool - Motley Fool - Thu May 05, 8:33AM CDT
While the market was in nearly nonstop rally mode for most of the past six years, investors didn't need to look far to uncover an abundance of growth stocks. But not all growth stocks are created equal. While some look poised to deliver extraordinary...
WYN: 69.69 (-1.33), SCMP: 11.89 (+0.14), NVR: 1,698.00 (-7.00)
Sucampo reports 1Q loss
Automated Insights - Wed May 04, 5:38AM CDT
ROCKVILLE, Md. (AP) _ Sucampo Pharmaceuticals Inc. (SCMP) on Wednesday reported a first-quarter loss of $4.1 million, after reporting a profit in the same period a year earlier.
SCMP: 11.89 (+0.14)
Sucampo Reports Strong Results for First Quarter of 2016
GlobeNewswire - Wed May 04, 5:30AM CDT
Results Driven by 60% Growth in Revenue
SCMP: 11.89 (+0.14)
Sucampo Pharmaceuticals Announces Webcast of Its Presentation at the Bank of America Merrill Lynch 2016 Healthcare Conference
GlobeNewswire - Tue May 03, 5:45AM CDT
Sucampo Pharmaceuticals, Inc. (Sucampo) (Nasdaq:SCMP), a global biopharmaceutical company, today announced that it will webcast its corporate presentation at the Bank of America Merrill Lynch 2016 Healthcare Conference on Tuesday, May 10 at 11:20 AM PT or 2:20 PM ET.
SCMP: 11.89 (+0.14)
CORRECTING and REPLACING Sucampo Standardizes on Veeva Vault for a Single Source of Truth and Enterprise-wide Capability
BusinessWire - Thu Apr 28, 9:44AM CDT
Headline of release should read: Sucampo Standardizes on Veeva Vault for a Single Source of Truth and Enterprise-wide Capability (instead of Sucampo Standardizes on Veeva Vault for a Single Source of Truth Enterprise-wide)
VEEV: 38.27 (+0.28), SCMP: 11.89 (+0.14)
Newest Release of Veeva Vault Streamlines Global Business Processes to Get Products to Market Faster and More Efficiently
BusinessWire - Thu Apr 28, 6:03AM CDT
Veeva Systems (NYSE: VEEV) introduced innovative features in its newest release of Veeva Vault, version 14. The Veeva Vault platform and suite of enterprise applications empower life sciences companies to streamline their business processes across an increasingly broad ecosystem of internal and external stakeholders.
VEEV: 38.27 (+0.28), SCMP: 11.89 (+0.14)
Sucampo Standardizes on Veeva Vault for a Single Source of Truth Enterprise-wide
BusinessWire - Thu Apr 28, 6:03AM CDT
Veeva Systems (NYSE:VEEV) announced today that Sucampo Pharmaceuticals (NASDAQ:SCMP), a fast-growing global biopharmaceutical company, has standardized on the Veeva Vault platform and suite of applications to provide a unified foundation for content and information management. Veeva's solution will help Sucampo eliminate information and process siloes across functional teams, regions, and partners, enabling Sucampo to make information fully accessible and actionable. Veeva Vault allows Sucampo to increase efficiency and strengthen compliance with a single source of truth for content plus life sciences-specific solutions that streamline key processes throughout the product lifecycle.
VEEV: 38.27 (+0.28), SCMP: 11.89 (+0.14)
Sucampo Announces First Quarter 2016 Earnings Call
GlobeNewswire - Wed Apr 20, 5:45AM CDT
Sucampo Pharmaceuticals, Inc. (Sucampo) (NASDAQ:SCMP), a global biopharmaceutical company, today announced that it will host its first quarter 2016 financial results teleconference and webcast at 8:30 a.m. Eastern on Wednesday, May 4th. The press release announcing the financial results and operating highlights is expected to be released before the opening of capital markets that day.
SCMP: 11.89 (+0.14)
Sucampo Reports Top-Line Data from Phase 2a Study of Cobiprostone in Patients with PPI-Refractory Non-Erosive Reflux Disease (NERD) and Symptomatic Gastroesophageal Reflux Disease (sGERD)
GlobeNewswire - Tue Apr 19, 6:00AM CDT
Sucampo Pharmaceuticals, Inc. (Sucampo) (NASDAQ:SCMP), a global biopharmaceutical company, today announced top-line data from a Phase 2a study of cobiprostone in patients with proton pump inhibitor (PPI)-refractory non-erosive reflux disease (NERD) or symptomatic gastroesophageal reflux disease (sGERD). While cobiprostone demonstrated significant benefit in some of the secondary measures of this exploratory study, the trial did not meet its primary endpoints and, based on these data, Sucampo intends to discontinue development of cobiprostone for PPI-refractory NERD/sGERD.
SCMP: 11.89 (+0.14)
Valeant (VRX) Receives Notice of Default: Stock in Trouble?
Zacks Equity Research - Zacks Investment Research - Wed Apr 13, 10:50AM CDT
Valeant Pharmaceuticals International, Inc. (VRX) announced that it has received a notice of default from its debtors.
VRX: 20.89 (-1.41), ARQL: 1.68 (+0.02), SCMP: 11.89 (+0.14), AMAG: 27.02 (+0.49)
Intercept's (ICPT) Ocaliva Gets Favorable FDA Panel Vote
Zacks Equity Research - Zacks Investment Research - Fri Apr 08, 2:35PM CDT
Intercept Pharmaceuticals, Inc. (ICPT) announced that the FDA's Gastrointestinal Drugs Advisory Committee has voted unanimously in favor of the company's lead pipeline candidate, Ocaliva.
ARQL: 1.68 (+0.02), SCMP: 11.89 (+0.14), ICPT: 169.72 (-3.31)
Intercept (ICPT) Up Ahead of Advisory Committee Meeting
Zacks Equity Research - Zacks Investment Research - Wed Apr 06, 10:10AM CDT
Shares of Intercept Pharmaceuticals, Inc. (ICPT) surged 13.3% just before the FDA Gastrointestinal Drug Advisory Committee's (GIDAC) meeting scheduled for Apr 7, 2016.
ECYT: 3.18 (unch), ARQL: 1.68 (+0.02), SCMP: 11.89 (+0.14), ICPT: 169.72 (-3.31)
